NEW YORK (GenomeWeb News) – Mitomics today announced that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.
The PCM test is based on mitochondrial DNA and identifies a biomarker that indicates the presence of cancerous cells in prostate biopsy tissue. Thunder Bay, Ontario-based Mitomics said the test has a sensitivity of 84 percent with a negative predictive value of 91 percent.
"This agreement supports our ongoing strategy to expand access to our prostate cancer testing technology through strategic collaborations as well as through direct sales by our field force," Mitomics President and CEO Robert Poulter said in a statement.
Atlanta-based LabMD is a clinical pathology lab focused on the urology office market.